Navigation Links
Researchers identify proteins in lung cancer cells that may provide potential drug targets
Date:11/24/2009

(Boston) Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy. In addition, the BU researchers have developed a new computational strategy to analyze this data and specifically identify key biological pathways (molecular circuits) that are active in cancer and "dormant" in normal cells. The study which appears in the November 25th issue of PLoS ONE, will ultimately lead to the development of drugs specifically aimed to inhibit these proteins.

According to the BU researchers, there are many features that make cancer cells different from normal cells. They look different histologically, they proliferate and divide at different rates, they are immortal unlike normal cells, and are less communicative with their neighbor cells. They are also more "selfish" in refusing to commit suicide (programmed cell death) which normal cells do when their genomes become unstable.

Much of the cellular machinery involved with these biological processes is controlled by a command control and communication system called signal transduction. Signal transduction is in large part controlled by a process called phosphorylation. When a protein is phosphorylated it either becomes active or repressed depending on its special function. "Therefore, identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior author Simon Kasif, PhD, who is the co-director of the Center of Advanced Genomic Technology and a professor in the department of biomedical engineering at BU. "Drugs are most effective on cancers when they attack the proteins that are activated," he added.

While cancers are highly heterogeous in their make-up, the BU researchers believe that a drug that would target this collection of proteins would be effective treatment for most lung cancers.

"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," explained senior co-author Martin Steffen, MD, PhD, an assistant professor of pathology and laboratory medicine at BUSM, and director, Proteomics Core Facility at BUSM.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
2. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
3. Researchers identify role of gene in tumor development, growth and progression
4. On the trail of a vaccine for Lyme disease: Yale researchers target tick saliva
5. UCLA researchers create fly paper to capture circulating cancer cells
6. Researchers focus on helping dying patients take care of unfinished business
7. Mount Sinai researchers to test first gene therapy For Alzheimers patients
8. Wistar researchers show targeting normal cells in tumors slows growth
9. K-State researchers studying link between climate change and cattle nutritional stress
10. Cornell Researchers Identify a Weak Link in Cancer Cell Armor
11. Researchers notch a victory toward new kind of cancer drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Calif. (PRWEB) , ... March 24, 2017 , ... ... raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... instant demand for the product – with nearly 2,000 consumers (and counting) already ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, ... pleased to announce Westchester resident Lauren C. Enea has joined the firm as an ... will concentrate her practice in elder law, Medicaid planning and applications, and Wills, Trusts ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate about ... what is often a very difficult and challenging time.” , A Certified Medical ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... inspiring stories about real people of God in congregations across the United States. ... a Presbyterian minister ordained in 1964 who has served congregations in seven states ...
(Date:3/23/2017)... ... , ... The physicians of KSF Orthopaedic Center PA are proud to announce ... is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside ... patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... in Drug Discovery and Diagnostics, 2017 - 2035" report to ... The ... current landscape and future outlook of the growing market of deep ... data revolution, deep learning algorithms have emerged as a novel solution ...
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
(Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
Breaking Medicine Technology: